MetaCap

BioNTech (BNTX) vs Krystal Biotech (KRYS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Krystal Biotech (KRYS) has outperformed BioNTech (BNTX) over the past year, gaining 45.7% versus a loss of 15.3%. Over five years, KRYS leads with a +675.9% price change compared with -76.7% for BNTX. BioNTech is the larger company by market cap ($20.07 billion vs $9.15 billion), about 2.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BNTX-15.30%KRYS+45.69%
+83%+32%-20%
Nov 21, 20251 yearNov 20, 2026
BNTX-72.06%KRYS+489.82%
+651%+272%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BNTX versus KRYS key metrics
MetricBNTXKRYS
Share price$80.96$308.89
Market cap$20.07B$9.15B
1-day change-0.52%-2.19%
YTD return-14.96%+25.29%
1-year return-15.30%+45.69%
5-year return-76.74%+675.91%
P/E ratio (TTM)—41.97
Forward P/E—33.47
EPS (TTM)$-6.83$7.36
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$389.13M
Revenue growth (YoY)—+33.94%
Net income (latest FY)—$204.83M
Operating margin—41.45%
Net margin—52.64%
52-week high$124.00$382.54
52-week low$79.52$212.02
Distance from 52-week high-34.71%-19.25%
Analyst consensusbuystrong_buy
Avg. price target upside+38.51%+25.68%
Average volume1.08M283.88K
Shares outstanding247.93M29.63M
Employees7,807295
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BioNTech is about 2.2 times larger than Krystal Biotech by market value ($20.07B vs $9.15B).
  • KRYS has outperformed BNTX by 61.0 percentage points over the past year.

About BioNTech

BNTX stock →

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees

About Krystal Biotech

KRYS stock →

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees

BNTX vs KRYS FAQ

Which is bigger, BioNTech or Krystal Biotech?

BioNTech (BNTX) is larger, with a market capitalization of $20.07B compared with $9.15B for Krystal Biotech (KRYS).

Which stock has performed better over the past year, BNTX or KRYS?

KRYS returned +45.69% over the past 12 months, compared with -15.30% for BNTX (price return, excluding dividends). Past performance does not predict future results.

Are BioNTech and Krystal Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons